Animace načítání

Stránka se připravuje...

Přihlásit se Registrovat se
28 608 právních předpisů

Další údaje zde

Technická podpora

Poskytujeme technickou podporu zdarma

Zavolejte nám

+420 777 717 492

Plné znění - 32020R1182

  1. Úvodní strana
  2. Právní předpisy EU
  3. Plné znění - 32020R1182

Na co čekáte? Nečekejte už ani minutu.
Získejte přístup na tento text ještě dnes. Kontaktujte nás a my Vám obratem uděláme nabídku pro Vás přímo na míru.

Chci získat výhodný přístup

XXXXXXXX KOMISE X XXXXXXXXX XXXXXXXXX (XX) 2020/1182

xx xxx 19. xxxxxx 2020,

xxxxxx xx xxx xxxxx přizpůsobení xxxxxxxxxxx a xxxxxxxxx xxxxxxx xxxx xxxx 3 xxxxxxx VI xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Rady (XX) x. 1272/2008 x xxxxxxxxxxx, označování x xxxxxx xxxxx a xxxxx

(Xxxx x xxxxxxxx xxx XXX)

XXXXXXXX XXXXXX,

x xxxxxxx xx Xxxxxxx x xxxxxxxxx Xxxxxxxx xxxx,

x ohledem na xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx (XX) x. 1272/2008 xx xxx 16. xxxxxxxx 2008 x klasifikaci, xxxxxxxxxx x balení xxxxx x xxxxx, x xxxxx x xxxxxxx xxxxxxx 67/548/XXX x 1999/45/XX x x xxxxx xxxxxxxx (XX) x. 1907/2006&xxxx;(1), x xxxxxxx xx xx. 37 odst. 5 xxxxxxxxx xxxxxxxx,

xxxxxxxx x xxxxx xxxxxxx:

(1)

Xxxxxxx 3 x části 3 xxxxxxx XX xxxxxxxx (XX) č. 1272/2008 obsahuje seznam xxxxxxxxxxxxxxx xxxxxxxxxxx x xxxxxxxx nebezpečných xxxxx xx xxxxxxx kritérií xxxxxxxxxxx v xxxxxxx 2 až 5 xxxxxxx X uvedeného xxxxxxxx.

(2)

Xxxxxxxx agentuře pro xxxxxxxx xxxxx („xxxxxxxx“) xxxx x xxxxxxx x článkem 37 xxxxxxxx (ES) x. 1272/2008 předloženy návrhy xx xxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxx x xxxxxxxx xxxxxxxxx látek x xxxxxxxxxxx nebo xxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxx x xxxxxxxx některých xxxxxx xxxxx. Xx základě xxxxxxxxxx&xxxx;(2) k xxxxx xxxxxxx, které xxxxx Xxxxx xxx xxxxxxxxxx xxxxx („RAC“) xxxxxxxx, xxxxx x xxxxxxxxxx xxxxxxxxxxxx xxxxx, xx xxxxxx xxxxxx, xxxxxxxxxxxx xx xxxxxx xxxxxxxxxxxxx xxxxxxxxxxx a označení xxxxxxxxx xxxxx. Xxxxxxx xxxxxxxxxx xxxxxx RAC xxxx:

—

xxxxxxxxxx xx dne 8. xxxxxx 2018 xxxxxxx kyseliny xxxxxxx... %[X ≤ 70 %],

—

xxxxxxxxxx ze xxx 9. xxxxxx 2018 xxxxxxx vláken z xxxxxxx xxxxxxx (x xxxxxxx < 3 μx,xxxxx &xx; 5 μx x poměru xxxxx ≥ 3:1),

—

stanovisko xx xxx 8. xxxxxx 2018 ohledně xxxxxxxxxxxxxxxxxxxxx, xxxxxxxxxx(xxxxx)xxxxxx,

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 xxxxxxx tris(2-methoxyethoxy)vinylsilanu, 6-(2-xxxxxxxxxxxxx)-6-xxxxx-2,5,7,10-xxxxxxxx-6-xxxxxxxxxxxx,

—

xxxxxxxxxx xx dne 8. xxxxxx 2018 xxxxxxx xxxxxxxx-xxxxxxxxx,

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 ohledně xxxxxxxxxxx xxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx bis (N-hydroxy-N-nitrosocyklohexylaminato-O,O’)-mědi, xxx(X-xxxxxxxxxx-xxxxxxxxx-xxxxx)-xxxx, [Xx-XXX],

—

xxxxxxxxxx xx xxx 14. xxxx 2018 xxxxxxx dioktyltin-dilaurátu, [1] xxxxxxxx, xxxxxxx-, xxx(xxxx xxxxxxx) xxxxxxxx [2],

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx xxxxxxx[xxx,x]xxxxxxxx, xxxxxxx[x,x]xxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx xxxxxxxxxx (ISO), (1XX,2XX,5XX;1XX,2XX,5XX)-2-(4-xxxxxxxxxxx)-5-xxxxxxxxx-1-(1X-1,2,4-xxxxxxx-1-xxxxxxxx)xxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 xxxxxxx xxx(2-(2-xxxxxxxxxxxxx)xxxxx)xxxxxx, xxxxxxxxxx,

—

xxxxxxxxxx ze xxx 8. xxxxxx 2018 xxxxxxx xxxxxxxxxxxxxx (XXX), (2XX,3XX)-1-(4-xxxxxxxxxxx)-4,4-xxxxxxxx-2-(1X-1,2,4-xxxxxxx-1-xx)xxxxxx-3-xxx,

—

xxxxxxxxxx ze xxx 8. xxxxxx 2018 xxxxxxx 2,2-xxx(xxxxxxxxxx)xxxxxx-1,3-xxxxx,

—

xxxxxxxxxx xx xxx 14. xxxx 2018 xxxxxxx xxxxxxxxx, (2X)-3,7-xxxxxxxxxxxx-2,6-xxxx-1-xxx,

—

xxxxxxxxxx xx xxx 28. xxxxx 2019 xxxxxxx 2-(4-terc-butylbenzyl)propionaldehydu,

—

stanovisko xx xxx 9. xxxxxx 2018 xxxxxxx XXXX-xxxxxxxxxx (ISO), S-ethyl (4-xxxxx-2-xxxxxxxxxxxx)xxxxxxxxxxxxx, X-xxxxx 4-chlor-o-tolyloxythioacetátu,

—

stanovisko xx xxx 9. xxxxxx 2018 xxxxxxx xxxxxxxxxx-xxxxxxx,

—

xxxxxxxxxx ze xxx 14. xxxx 2018 xxxxxxx 4-{[(6-xxxxxxxxxxxxx-3-xx)xxxxxx](2,2-xxxxxxxxxxxxx)xxxxx}xxxxx-2(5X)-xxx, xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx dne 30. xxxxxxxxx 2018 ohledně xxxxxxxxxxxxx-xxxxxxx (XXX), xxxxxx 4- [(4,5-xxxxxxx-3-xxxxxxx-4-xxxxxx-5-xxx-1X-1,2,4-xxxxxxx-1-xx)xxxxxxxxxxxxxxxxx]-5-xxxxxxxxxxxxx-3-xxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx X-(+)-xxxxxx xxxxxxxx, (2S)-2-hydroxypropanové xxxxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx 2-xxxxxxxxxxxx-xxxxxxxx,

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 xxxxxxx glyoxylové kyseliny …%,

—

xxxxxxxxxx xx dne 14. xxxx 2018 xxxxxxx xxxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxxx, [xxxxxxxxxxx xxxxxxxx x xxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxxx],

—

xxxxxxxxxx xx dne 30. xxxxxxxxx 2018 ohledně (xxxxx-XXX-xxxxx)xxxxxxxxxxx xxxxxxxxxx, xxxxxxxxxx(xxxxxxx)xxxxxx-1-xxxxx, xxxxxxxx xxxx, [X-XXX],

—

xxxxxxxxxx xx xxx 14. xxxx 2018 xxxxxxx xxxxxxxxxxx-xxxxxxxxxxx, N-ethyl-N,N-dimethylhexadekan-1-aminium-ethyl-sulfátu, mecetronium-ethyl-sulfátu [XXX],

—

xxxxxxxxxx xx dne 9. xxxxxx 2018 xxxxxxx (2XX)-2-[4-(4-xxxxxxxxxxx)-2(xxxxxxxxxxxxxxx)xxxxx]-1-(1X-1,2,4-xxxxxxx-1-xx)xxxxxx-2-xxx, mefentriflukonazolu,

—

stanovisko xx xxx 30. xxxxxxxxx 2018 ohledně xxxxxxxxxxxxxxxx (ISO), 1-(4-{4-[5-(2,6-xxxxxxxxxxxx)-4,5-xxxxxxx-1,2-xxxxxx-3-xx]-1,3-xxxxxxx-2-xx}xxxxxxxxx-1-xx)-2-[5-xxxxxx-3-(xxxxxxxxxxxxxxx)-1X-xxxxxxx-1-xx]xxxxxxxx,

—

xxxxxxxxxx xx xxx 14. xxxx 2018 xxxxxxx xxxxxxxxx-xxxxx, (X-4)-xxx[1-(xxxxxxx-xxxxx-X)xxxxxxx-2(1X)-xxxxxxx-xxxxx-X]xxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx 3-xxxxx-4-(xxxxxxxxxxx)-1-[3-xxxxxxxxxxxxxx)xxxxx]xxxxxxxxxx-2-xxx, xxxxxxxxxxxxxxx (XXX),

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx 4,5-dichlor-2-oktyl-2H-isothiazol-3-onu, [XXXXX],

—

xxxxxxxxxx xx dne 8. června 2018 xxxxxxx 2-xxxxxx-1,2-xxxxxxxxxxxx-3(2X)-xxx, [MBIT],

—

stanovisko xx xxx 30. xxxxxxxxx 2018 ohledně 3-(xxxxxxxxxxxxx)-1-xxxxxx-X-(3‘,4’,5’xxxxxxxxxxxxxxx-2-xx)xxxxxxx-4-xxxxxxxxxxx, fluxapyroxadu,

—

stanovisko ze xxx 8. xxxxxx 2018 ohledně X-(xxxxxxxxxxxxx)xxxxxxxxxx, xxxxxxxxxxxxxxxxxx, [XXX],

—

xxxxxxxxxx xx xxx 15. xxxxx 2018 xxxxxxx 5-xxxxx-1,3-xxxxxxxx-X-[2-(4-xxxxxxxxxxxx-2-xx)xxxxx]-1X-xxxxxxx-4-xxxxxxxxxxx, 2’-[(XX)-1,3-xxxxxxxxxxxxx]-5-xxxxx-1,3-xxxxxxxxxxxxxxx-4-xxxxxxxxxxxxx, xxxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxxxxxx (XXX), xxxxxxxxx [(2S)-3-methyl-1-{[1-(4-methylfenyl)ethyl]amino}-1-oxobutan-2-yl]karbamátu,

—

stanovisko xx dne 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxxxx (XXX), X-xxxxx-4,5-xxxxxxxx-2(xxxxxxxxxxxxxx)xxxxxxx-3-xxxxxxxxxxx,

—

xxxxxxxxxx xx dne 9. xxxxxx 2018 xxxxxxx xxxxxxx, xxxxxxx [olej xxxxxxxx za xxxxxxx xx semen xxxxxxxx Xxxxxxxxxxx indica xxx xxxxxxxx, xxxxxxxxxxx superkritickým xxxxxx xxxxxxxxx],

—

xxxxxxxxxx ze xxx 8. června 2018 xxxxxxx xxxxxxxx xxxxxxx …%[X&xx; 70 %],

—

xxxxxxxxxx x 9. xxxxxx 2018 ohledně xxxxxxxxxxxxxxxxxxxxxxxxxxxx, [X4],

—

xxxxxxxxxx ze xxx 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxx-xxxxxxx (XXX), O-[2-(diethylamin)-6-methylpyrimidin-4-yl]-O,O-dimethyl-fosforthioátu,

—

stanovisko xx 30. listopadu 2018 xxxxxxx xxxxxxx,

—

xxxxxxxxxx xx xxx 14. xxxx 2018 xxxxxxx xxxxxxxxxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 ohledně 2-xxxxxxxxxx-10-xxxxx-4,4-xxxxxxx-7-xxx-8-xxx-3,5-xxxxxx-4-xxxxxxxxxxx-xxxxxxxxx, [XXXX],

—

xxxxxxxxxx ze xxx 30. xxxxxxxxx 2018 ohledně xxxxx,

—

xxxxxxxxxx xx xxx 14. xxxx 2018 ohledně 2-xxxxxxxxxxxxxx, xxxxxxxxxxxxx-xxxxxxxxx-xxxxxx,

—

xxxxxxxxxx xx xxx 30. listopadu 2018 xxxxxxx x-xxx(2,3-xxxxxxxxxxxx)xxxxxxx, xxxxxxxxxx-xxxxxxxxxx-xxxxxx,

—

xxxxxxxxxx xx xxx 14. xxxx 2018 xxxxxxx xxxxxxxxxx-xxxxxxx (XXX), xxxxxx 2-[X-(4-xxxxxxx-6-xxxxxx-1,3,5-xxxxxxx-2-xx)-X-xxxxxxxxxxxxxxxxxxxxxxxx]xxxxxxxx,

—

xxxxxxxxxx xx xxx 8. června 2018 ohledně xxxxxxxxxxxxx (XXX), xxxxxx (X)-2-{2-[6-(2-xxxxxxxxxxx)xxxxxxxxx-4-xxxxx]xxxxx}-3-xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx xxxxxxxxxxxx (XXX), (XX)-2-xxxxxx-2,3-xxxxxxx-3,3-xxxxxxxxxxxxxxxxxx-5-xx-xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx 2,4-xxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 14. xxxx 2018 xxxxxxx xxxxxxxxxx (ISO), 2-[4-(xxxxxxxxxxxxxx)-2-xxxxxxxxxxxx]-1,3-xxxxxxxxxxxxxxx,

—

xxxxxxxxxx ze dne 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxxxx (ISO), 2-xxxxx-2X-xxxxxxxxxx-3-xxx, [XXX],

—

xxxxxxxxxx ze xxx 14. xxxx 2018 xxxxxxx xxxxxxxxxx (XXX), 3-xxxxxxx-5-xxxxxxxxxxxxxxx,

—

xxxxxxxxxx ze xxx 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxxxxx (XXX), trans-5-(4-chlorfenyl)-N-cyklohexyl-4-methyl-2-oxo-3-thiazolidin-karboxamidu,

—

stanovisko xx xxx 9. xxxxxx 2018 xxxxxxx xxxxxxxxxxx (XXX), (X)-4,5-xxxxxxx-6-xxxxxx-4-(3-xxxxxxxxxxxxxxx-xxxxx)-1,2,4-xxxxxxx-3(2X)-xxx,

—

xxxxxxxxxx xx xxx 9. března 2018 xxxxxxx imiprothrinu (XXX), xxxxxxx xxxxx: [2,4-xxxxx-(2-xxxxxx-1-xx)xxxxxxxxxxxx-3-xx]xxxxxx(1X)-xxx-xxxxxxxxxxxxxx, [2,4-dioxo-(2-propyn-1-yl)imidazolidin-3-yl]methyl(1R)-trans-chrysanthematu,

—

stanovisko xx xxx 14. září 2018 xxxxxxx-xxxxx, ethylmethylketoximu, xxxxxxxxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx dne 8. xxxxxx 2018 xxxxxxx xxx(α,α-xxxxxxxxxxxxxx)-xxxxxxxx,

—

xxxxxxxxxx ze xxx 9. xxxxxx 2018 ohledně xxxxxxxxxxxx xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx xxxxx 2-(1-(diethylaminohydroxyfenyl) xxxxxxxxx)xxxxxxxx, xxxxx 2-[4-(diethylamin)-2-hydroxybenzoyl]benzoátu.

(3)

Pokud xxx x xxxxx xxxxx (číslo CAS 7439–92–1 a xxxxxxxx xxxxx 082–013–00–1 (xxxxx x prášku; [xxxxxx xxxxxx < 1 xx];) x 082–014–00–7 (xxxxxxxx xxxxx; [xxxxxx xxxxxx ≥ 1 xx];)), XXX xx xxxx stanovisku xx xxx 30. xxxxxxxxx 2018 xxxxxx xxxxxx xxxxxxx environmentální klasifikaci xx xxxxxxxxx x xxxxxxxxx xxxxx. Xxxxx xxxxxxxx x nižší xxxxxxxxx rozpouštění celistvé xxxxx, xxxxxx struktuře xxxxx, xx xxxxxxxxxx xxxxxxx výrobě prášku x xxxxxxxx x xxxxx xxxxxxxxxxxxxxx xxxxxxxxxxx x xxxxxxxxxx x xxxxxxxxxx xxxxx xxxxxx xxxx x xxxxxxxxxxxx xxxxxxxxx v xxxxxxx XX xxxx XXX xxxxxxx xxxxx posouzení xxxx, zda xx xxx na xxxxxxxxx x xxxxxxxxx formu xxxxx xxxxxxx stejná xxxxxxxxxxxxxxx xxxxxxxxxxx. Kromě xxxx byly xxxxxxxxxx xxxx xxxxxxx poznatky, x nichž xxxxxxx, xx xxxxxxxxxxxxxxx xxxxxxxxxxx xxx xxxxxxxxx formu, xxx xx xxxxxxxxxx xxxxxxxxxx xxxxxx XXX, xxxxxx xxx xxxxxx. Xxxxxxxxxxxxxxx xxxxxxxxxxx xxx xxxxxxxxx formu proto xxxxxx zařazena do xxxxxxx XX nařízení (XX) x. 1272/2008, xxxxx XXX nebude xxx xxxxxxx xxxxxxxxx xxxxxxxxxx xxxxxxxxxx.

(4)

Xxxxx xxx x látku 2-butoxyethanol, xxxxxxxxxxxxx-xxxxxxxxx-xxxxx, (xxxxx XXX 111-76-2), xxx xxxxx xxxxxxxxxxxxx „xxxxxx xxxxxxxx (xxxxxxxxx)“ xxxx xxxxxxxxxx xxxx xxxxxxx xxxxxxxx, xx xxxxxxx vyplývá, xx klasifikace xxx xxxx xxxxx nebezpečnosti xxxxxxxxxxxx xx xxxxxxxxxx xxxxxx XXX, xxx xx xxxxxxx na xxxxxxxx xxxxxxx, xxxxxx xxx vhodná. Tato xxxxx xxxxxxxxxxxxx xx xxxxx xxxxxx být x xxxxxxx XX xxxxxxxx (XX) x. 1272/2008 změněna, xxxxx XXX nebude mít xxxxxxx xxxxxxxxx x xxxxx xxxxx xxxxxxxxxx xxxxxxxxxx xxxxxxxxxx; všechny xxxxxxx xxxxx xxxxxxxxxxxxx, x kterých xxxxxxxxx xxxxxxxxxx xxxxxx RAC, xx zařazeny xxx xxxx.

(5)

Xxxxxxxx (XX) x. 1272/2008 xx xxxxx xxxx být xxxxxxxxxxxxx xxxxxxxx xxxxxxx.

(6)

Xxxxxxxxxx nových xxxx xxxxxxxxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxx by xxxxxx xxx, x výhradou xxxxxxxxxxx regulatorních xxxxxxxxx, xxxxxxxxxx xxxxx, xxxxxxx xxxxxxxxxx potřebují xxxxxxx xxxx na to, xxx přizpůsobili xxxxxxxxxx x xxxxxx xxxxx x xxxxx xxxxx xxxx revidovaným klasifikacím x prodali xxxxxxxxx xxxxxx. Xxxx xxxx xx xxxxxx nezbytná x xxxx, xxx xxxxxxxxxx měli xxxxxxxx xxxx xxxxxxxx opatření xxxxx x xxxxxxxxx xxxxxxxx xxxxxxxxxx dalších xxxxxxxx xxxxxxxxx, xxxxx xxxxxxxx x xxxxxxxx xxxx xxxxxxxxxxx xxxxx xxxxxx nařízení. Tyto xxxxxxxxx xxxxx xxxxxxxxx xxxxxxxxx stanovené x xx. 22 xxxx. 1 xxxx. x) xxxxxxxx Evropského xxxxxxxxxx x Rady (XX) x. 1907/2006 (3) nebo xxxxxxxxx stanovené x xxxxxx 50 nařízení Xxxxxxxxxx parlamentu a Xxxx (XX) x. 528/2012&xxxx;(4).

(7)

Xxxxxxxxxxx by však xxxx xxx xxxxxxxx, xxx mohli xxxx xxxxxxxxxx xxxxxxxx xx xxxxxxxxxxx, xxxxxxxxxx x xxxxxx uplatňovat dobrovolně xxxxx xxxx použitelnosti xxxxxx xxxxxxxx. Xx xx x xxxxxxx x xxxxxxxxx podle xx. 61 xxxx. 2 xxxxxxxx (XX) x. 1272/2008,

PŘIJALA XXXX XXXXXXXX:

Článek 1

Změny xxxxxxxx (XX) x. 1272/2008

Xxxxxxx 3 x xxxxx 3 xxxxxxx XX xxxxxxxx (ES) x. 1272/2008 xx mění x souladu x xxxxxxxx xxxxxx nařízení.

Xxxxxx 2

Xxxxx x xxxxxxxx x použitelnost

Toto xxxxxxxx vstupuje v xxxxxxxx xxxxxxxx xxxx xx xxxxxxxxx x Xxxxxxx věstníku Xxxxxxxx xxxx.

Xxxxxxx xx ode xxx 1. xxxxxx 2022.

Xxxxxxxx xx xxxxxxx xxxxxxxxxxx xxxxxx xxxxxx xxxxx xxx látky x xxxxx klasifikovány, xxxxxxxxxx x xxxxxx x souladu s xxxxxxxxx (XX) x. 1272/2008 ve znění xxxxxx xxxxxxxx xxxxx xxxxx xxxx 1. xxxxxx 2022.

Xxxx xxxxxxxx je xxxxxxx v celém xxxxxxx x xxxxx xxxxxxxxxx xx všech xxxxxxxxx xxxxxxx.

X Bruselu xxx 19. xxxxxx 2020.

Xx Komisi

Ursula XXX XXX LEYEN

předsedkyně

(1)  manaÚř. xxxx. X 353, 31.12.2008, x. 1.

(2)&xxxx;&xxxx;Xxxxxxxxxx xxxx xxxxxxxx xx této xxxxxxxxxxx xxxxxxx: https://echa.europa.eu/registry-of-clh-intentions-until-outcome/-/dislist/name/-/ecNumber/-/casNumber/-/dte_receiptFrom/-/dte_receiptTo/-/prc_public_status/Opinion+Adopted/dte_withdrawnFrom/-/dte_withdrawnTo/-/sbm_expected_submissionFrom/-/sbm_expected_submissionTo/-/dte_finalise_deadlineFrom/-/dte_finalise_deadlineTo/-/haz_addional_hazard/-/lec_submitter/-/dte_assessmentFrom/-/dte_assessmentTo/-/prc_regulatory_programme/-/

(3)  Nařízení Xxxxxxxxxx parlamentu x Xxxx (XX) č. 1907/2006 xx dne 18. prosince 2006

x xxxxxxxxxx, hodnocení, xxxxxxxxxx x omezování xxxxxxxxxx xxxxx, x zřízení Xxxxxxxx agentury pro xxxxxxxx xxxxx, x xxxxx xxxxxxxx 1999/45/XX x x zrušení xxxxxxxx Xxxx (EHS) x. 793/93, xxxxxxxx Xxxxxx (XX) x. 1488/94, xxxxxxxx Xxxx 76/769/XXX a směrnic Xxxxxx 91/155/EHS, 93/67/XXX, 93/105/XX a 2000/21/ES (Xx. věst. X 396, 30.12.2006, x. 1).

(4)&xxxx;&xxxx;Xxxxxxxx Xxxxxxxxxx parlamentu x Xxxx (EU) x. 528/2012 ze xxx 22. xxxxxx 2012

x dodávání biocidních xxxxxxxxx xx trh x xxxxxx xxxxxxxxx

(Xx. xxxx. X 167, 27.6.2012, s. 1).

PŘÍLOHA

V příloze XX xxxxxxxx (XX) x. 1272/2008 se xxxxxxx 3 v xxxxx 3 xxxx xxxxx:

1)

Xxxxxxxx xx xxxx položky:

Indexové xxxxx

Xxxxxxxx xxxxx

Xxxxx XX

Xxxxx XXX

Xxxxxxxxxxx

Xxxxxxxx

Xxxxxxxxxx xxxxxxx. limity, xxxxxxxxxxxxx xxxxxxx a XXX

Xxxxxxxx

Xxxx xxxx x xxxxxxxxx xxxxxxxxxxxxx

Xxxx xxxxxxxxxxxx xxx x xxxxxxxxxxxxx

Xxxx xxxxxxxxxxx xxxxxxx a xxxxxxxxxx xxxx

Xxxx xxxxxxxxxxxx xxx x xxxxxxxxxxxxx

Xxxx xxxxx. xxxxxxxxxxxx vět x xxxxxxxxxxxxx

„007-030-00-3

xxxxxxxx dusičná …% [X ≤ 70 %]

231-714-2

7697-37-2.

Xx. Xxx. 3

Xxxxx Tox. 3

Skin Xxxx. 1 X

X272

X331

X314

XXX03

XXX06

XXX05

Xxx

X272

X331

X314

XXX071

Xx. Xxx. 3; H272: X ≥ 65 %

xxxxxxxxx: XXX = 2,65 xx/x (páry)

Skin Xxxx. 1 X; X314: X ≥ 20 %

Xxxx Xxxx. 1X; H314: 5 % ≤ X &xx; 20 %

X“

„014-048-00-5

xxxxxx x xxxxxxx xxxxxxx (x xxxxxxx &xx; 3 μx, xxxxx &xx; 5 μx x s poměrem xxxxx ≥ 3:1)

206-991-8

409-21-2

308076-74-6

Xxxx. 1X

X350x

XXX08

Xxx

X350x“

„014-049-00-0

xxxxxxxxxxxxxxxxxxxx; xxxxxxxxxx(xxxxx)xxxxx

220-449-8

2768-02-7

Xxxx Sens. 1X

X317

XXX07

Xxx

X317“

„014-050-00-6

xxxx(2-xxxxxxxxxxxxx)xxxxxxxxxx;

6-(2-xxxxxxxxxxxxx)-6-xxxxx-2,5,7,10-xxxxxxxx-6-xxxxxxxxxxx

213-934-0

1067-53-4

Xxxx. 1X

X360XX

XXX08

Xxx

X360XX“

„016-098-00-3

xxxxxxxx-xxxxxxxx

210-871-0

624-92-0

Xxxx. Xxx. 2

Xxxxx Xxx. 3

Acute Xxx. 3

XXXX XX 3

XXXX SE 1

Eye Xxxxx. 2

Xxxx Sens. 1

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X225

X331

X301

X336

X370 (xxxxx xxxxxxx xxxxx, vdechnutí)

H319

H317

H400

H410

GHS02

GHS06

GHS08

GHS09

Dgr

H225

H331

H301

H336

H370 (xxxxx dýchací xxxxx, xxxxxxxxx)

X319

X317

X410

xxxxxxxxx: XXX = 5 xx/x (xxxx)

xxxxxx: XXX = 190 xx/xx XX

X = 1

X = 10“

„029-024-00-X

granulovaná xxx;

[xxxxx částic: xx 0,9 mm x xx 6,0 mm; xxxxx xxxxxx: od 0,494 xx 0,949 xx]

231-159-6

7440-50-8

Xxxxxxx Chronic 2

X411

XXX09

X411“

„029-025-00-5

xxx(X-xxxxxxx-X-xxxxxxxxxxxxxxxxxxxxxxxx-X,X’)xxx;

xxx(X-xxxxxxxxxx-xxxxxxxxx-xxxxx)-xxx;

[Xx-XXX]

239-703-4

312600-89-8

15627-09-5

Xxxx. Xxx. 1

Xxxxx Xxx. 4

XXXX XX 2

Xxx Xxx. 1

Aquatic Acute 1

Xxxxxxx Xxxxxxx 1

H228

H302

H373 (xxxxx)

X318

X400

X410

XXX02

XXX07

XXX08

XXX05

XXX09

Xxx

X228

X302

X373 (xxxxx)

X318

X410

xxxxxx: XXX = 360 xx/xx XX

X = 1

X = 1“

„050-031-00-9

xxxxxxxxxx-xxxxxxxx; [1]

xxxxxxx, xxxxxxx-, xxx(xxxx acyloxy) xxxxxxxx [2]

222-883-3 [1] 293-901-5 [2]

3648-18-8 [1] 91648-39-4 [2]

Repr. 1X

XXXX XX 1

H360D

H372 (imunitní xxxxxx)

XXX08

Xxx

X360X

X372 (xxxxxxxx xxxxxx)“

„601-092-00-0

xxxxxxx[xxx,x]xxxxxxx;

xxxxxxx[x,x]xxxxx

205-886-4

191-30-0

Xxxx. 1X

Xxxx. 2

X350

X341

XXX08

Xxx

X350

X341

Xxxx. 1X; X350: X ≥ 0,001 %“

„603-237-00-3

xxxxxxxxx (ISO);

(1RS,2SR,5RS;1RS,2SR,5SR)-2-(4-chlorbenzyl)-5-isopropyl-1-(1H-1,2,4-triazol-1-ylmethyl)cyklopentanol

–

125225-28-7

115850-69-6

115937-89-8

Repr. 1X

Xxxxx Xxx. 4

STOT XX 2

Xxxxxxx Xxxxxxx 1

X360X

X302

X373 (xxx, xxxx, xxxxx)

X410

XXX08

XXX07

XXX09

Xxx

X360X

X302

X373 (xxx, xxxx, xxxxx)

X410

xxxxxx: XXX = 500 xx/xx XX

X = 100“

„603-238-00-9

xxx(2-(2-xxxxxxxxxxxxx)xxxxx)-xxxxx; xxxxxxxxx

205-594-7

143-24-8

Xxxx. 1X

X360XX

XXX08

Xxx

X360XX“

„603-239-00-4

xxxxxxxxxxxxx (XXX);

(2XX,3XX)-1-(4-xxxxxxxxxx)-4,4-xxxxxxxx-2-(1X-1,2,4-xxxxxxx-1-xx)xxxxxx-3-xx

–

76738-62-0

Xxxx. 2

Xxxxx Xxx. 4

Xxxxx Tox. 4

Xxx Xxxxx. 2

Xxxxxxx Xxxxx 1

Xxxxxxx Chronic 1

X361x

X332

X302

X319

X400

X410

XXX08

XXX07

XXX09

Xxx

X361x

X332

X302

X319

X410

xxxxxxxxx: XXX = 3,13 mg/l (xxxxx xxxx xxxx)

xxxxxx: XXX = 490 xx/xx XX

X = 10

M = 10“

„603-240-00-X

2,2-bis(brommethyl)propan-1,3-diol

221-967-7

3296-90-0

Carc. 1X

Xxxx. 1X

X350

X340

XXX08

Xxx

X350

X340“

„603-241-00-5

xxxxxxxx;

(2X)-3,7-xxxxxxxxxxxx-2,6-xxxx-1-xx

203-377-1

106-24-1

Xxxx Xxxx. 1

X317

XXX07

Xxx

X317“

„605-041-00-3

2-(4-xxxx-xxxxxxxxxxx)xxxxxxxx

201-289-8

80-54-6

Xxxx. 1X

X360Xx

XXX08

Xxx

X360Xx“

„607-738-00-8

XXXX-xxxxxxxxx (XXX);

X-xxxxx (4-xxxxx-2-xxxxxxxxxxxx)xxxxxxxxxxxx; X-xxxxx 4-chlor-o-tolyloxythioacetát

246-831-4

25319-90-8

Acute Tox. 4

XXXX XX. 2

Aquatic Xxxxx 1 Xxxxxxx Xxxxxxx 1

X302

X373 (xxxxx)

X400

X410

XXX07

XXX08

XXX09

Xxx

X302

X373 (xxxxx)

X410

xxxxxx: XXX = 450 xx/xx XX

X = 10

M = 10“

„607-740-00-9

xxxxxxxxxx-xxxxxx

248-523-5

27554-26-3

Xxxx. 1B

H360FD

GHS08

Dgr

H360FD“

„607-741-00-4

4-{[(6-chlorpyridin-3-yl)methyl](2,2-difluorethyl)amino}furan-2(5H)-on; flupyradifuron

–

951659-40-8

Acute Xxx. 4

XXXX XX 2

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X302

X373 (xxxxxxxxx)

X400

X410

XXX07

XXX08

XXX09

Xxx

X302

X373 (xxxxxxxxx)

X410

xxxxxx: ATE = 500 mg/kg XX

X = 10

M = 10“

„607-742-00-X

xxxxxxxxxxxxx-xxxxxx (XXX);

xxxxxx-4-[(4,5-xxxxxxx-3-xxxxxxx-4-xxxxxx-5-xxx-1X-1,2,4-xxxxxxx-1-xx)xxxxxxxxxxxxxxxxx]-5-xxxxxxxxxxxxx-3-xxxxxxxxxx

–

317815-83-1

Xxxxxxx Acute 1

Xxxxxxx Xxxxxxx 1

X400

X410

XXX09

Xxx

X410

X = 1000

X = 1000“

„607-743-00-5

X-(+)-xxxxxx kyselina;

(2 S)-2-hydroxypropanová xxxxxxxx

201-196-2

79-33-4

Xxxx Xxxx. 1X

Xxx Xxx. 1

X314

X318

XXX05

Xxx

X314

XXX071“

„607-744-00-0

2-xxxxxxxxxxxxxxxxxxx

221-499-3

3121-61-7

Xxxx. Xxx. 3

Xxxx. 2

Xxxx. 1B

Acute Xxx. 3

Xxxxx Xxx. 4

Xxxx Corr. 1X

Xxx Xxx. 1

Xxxx Xxxx. 1

X226

X341

X360XX

X331

X302

X314

X318

X317

XXX02

XXX05

XXX06

XXX08

Xxx

X226

X341

X360XX

X331

X302

X314

X317

XXX071

xxxxxxxxx: XXX = 2,7 xx/x (páry)

orální: XXX = 404 xx/xx XX“

„607-745-00-6

xxxxxxxxxx xxxxxxxx …%

206-058-5

298-12-4

Xxx Dam. 1

Skin Xxxx. 1B

H318

H317

GHS05

GHS07

Dgr

H318

H317

B“

„607-746-00-1

natrium-N-(hydroxymethyl)glycinát;

[formaldehyd xxxxxxxx x xxxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxxx]

274-357-8

70161-44-3

Xxxx. 1X

Xxxx. 2

Xxxxx Tox. 4

Acute Xxx. 4

XXXX XX 3

Xxxx Irrit. 2

Xxx Xxxxx. 2

Skin Xxxx. 1

X350

X341

X332

X302

X335

X315

X319

X317

XXX08

XXX07

Xxx

X350

X341

X332

X302

X335

X315

X319

X317

xxxxxxxxx: XXX = 3 xx/x (xxxxx xxxx xxxx)

xxxxxx: XXX = 1&xxxx;100 xx/xx XX

8

9“

„611-181-00-6

(xxxxx-XXX-xxxxx)xxxxxxxxxx draselný;

cyklohexylhydroxydiazen-1-oxid, draselná xxx;

[X-XXX]

–

66603-10-9

Xxxx. Xxx. 1

Acute Xxx. 3

STOT RE 2

Xxxx Xxxxx. 2

Eye Xxx. 1

Aquatic Chronic 2

X228

X301

X373 (xxxxx)

X315

X318

X411

XXX02

XXX06

XXX08

XXX05

XXX09

Xxx

X228

X301

X373 (xxxxx)

X315

X318

X411

xxxxxx: XXX = 136 xx/xx XX“

„612-294-00-3

xxxxxxxxxxxxxxxxxxxxx;

X-xxxxx-X,X-xxxxxxxxxxxxxxxxx-1-xxxxxxx-xxxxx-xxxxxx;

xxxxxxxxxxx-xxxxx-xxxxxx;

[XXX]

221-106-5

3006-10-8

Xxxx Corr. 1

Xxx Xxx. 1

Xxxxxxx Xxxxx 1

Aquatic Chronic 1

X314

X318

X400

X410

XXX05

XXX09

Xxx

X314

X410

XXX071

X = 100

X = 1&xxxx;000 “

„613-331-00-6

(2XX)-2-[4-(4-xxxxxxxxxxx)-2-(xxxxxxxxxxxxxx)xxxxx]-1-(1X-1,2,4-xxxxxxx-1-xx)xxxxxx-2-xx;

xxxxxxxxxxxxxxxxxx

–

1417782-03-6

Xxxx Xxxx. 1

Xxxxxxx Acute 1

Xxxxxxx Xxxxxxx 1

X317

X400

X410

XXX07

XXX09

Xxx

X317

X410

X = 1

X = 1“

„613-332-00-1

xxxxxxxxxxxxxxx (XXX);

1-(4-{4-[5-(2,6-xxxxxxxxxxxx)-4,5-xxxxxxx-1,2-xxxxxx-3-xx]-1,3-xxxxxxx-2-xx}xxxxxxxxx-1-xx)-2-[5-xxxxxx-3-(xxxxxxxxxxxxxx)-1X-xxxxxxx-1-xx]xxxxxxx

–

1003318-67-9

Xxxxxxx Xxxxxxx 1

X410

XXX09

Xxx

X410

X = 1“

„613-333-00-7

xxxxxxxxx-xxxxx; (X-4)-xxx[1-(xxxxxxx-.xxxxx.X)xxxxxxx-2(1X)-xxxxxxxx-.xxxxx.X]xxxxx

236-671-3

13463-41-7

Xxxx. 1X

Xxxxx Xxx. 2

Xxxxx Xxx. 3

STOT XX 1

Xxx Dam. 1

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X360X

X330

X301

X372

X318

X400

X410

XXX08

XXX06

XXX05

XXX09

Xxx

X360X

X330

X301

X372

X318

X410

xxxxxxxxx: XXX = 0,14 xx/x (xxxxx xxxx xxxx)

xxxxxx: XXX = 221 xx/xx XX

X = 1&xxxx;000

X = 10“

„613-334-00-2

xxxxxxxxxxxxxx (XXX);

3-xxxxx-4-(xxxxxxxxxxx)-1-[3-(xxxxxxxxxxxxxx)xxxxx]xxxxxxxxxx-2-xx

262-661-3

61213-25-0

Xxxx. 1B

Acute Xxx. 4

Xxxx Xxxx. 1

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X360XX

X302

X317

X400

X410

XXX08

XXX07

XXX09

Xxx

X360XX

X302

X317

X410

xxxxxx: XXX = 500 xx/xx TH

M = 100

M = 100“

„613-335-00-8

4,5-xxxxxxx-2-xxxxx-2X-xxxxxxxxxx-3-xx; [DCOIT]

264-843-8

64359-81-5

Acute Xxx. 2

Xxxxx Xxx. 4

Xxxx Xxxx. 1

Xxx Xxx. 1

Xxxx Xxxx. 1 X

Xxxxxxx Acute 1

Xxxxxxx Xxxxxxx 1

X330

X302

X314

X318

X317

X400

X410

XXX06

XXX05

XXX09

Xxx

X330

X302

X314

X317

X410

XXX071

xxxxxxxxx: ATE = 0,16 mg/l (xxxxx xxxx xxxx)

xxxxxx: XXX = 567 xx/xx XX

Xxxx Irrit. 2; H315: 0,025 % ≤ X &xx; 5 %

Xxx Xxxxx. 2; X319: 0,025 % ≤ X < 3 %

Xxxx Xxxx. 1 X; X317: C ≥ 0,0015 %

X = 100

X = 100“

„613-336-00-3

2-xxxxxx-1,2-xxxxxxxxxxxx-3(2X)-xx;

[XXXX]

–

2527-66-4

Xxxxx Xxx. 4

Acute Xxx. 3

Xxxx Xxxx. 1X

Xxx Dam. 1

Xxxx Xxxx. 1 A

Aquatic Xxxxx 1

Xxxxxxx Xxxxxxx 2

X312

X301

X314

X318

X317

X400

X411

XXX06

XXX05

XXX09

Xxx

X312

X301

X314

X317

X410

XXX071

xxxxxxxx: ATE = 1&xxxx;100 xx/xx TH

orální: XXX = 175 xx/xx XX

Xxxx Xxxx. 1 A; X317: X ≥ 0,0015 %

X = 1“

„616-228-00-4

3-(xxxxxxxxxxxxx)-1-xxxxxx-X-(3‘,4’,5’-xxxxxxxxxxxxxxx-2-xx)xxxxxxx-4-xxxxxxxxxx;

xxxxxxxxxxxx

–

907204-31-3

Xxxx.

Xxxxxxx Xxxxx 1

Xxxxxxx Chronic 1

X362

X400

X410

XXX09

Xxx

X362

X410

X = 1

M = 1“

„616-230-00-5

N-(hydroxymethyl)akrylamid; methylolakrylamid; [XXX]

213-103-2

924-42-5

Xxxx. 1X

Xxxx. 1B

STOT XX 1

X350

X340

X372 (periferní xxxxxxx xxxxxx)

XXX08

Xxx

X350

X340

X372 (xxxxxxxxx xxxxxxx systém)“

„616-231-00-0

5-fluor-1,3-dimethyl-N-[2-(4-methylpentan-2-yl)fenyl]-1H-pyrazol-4-karboxamid; 2’-[(RS)-1,3-dimethylbutyl]-5-fluor-1,3-dimethylpyrazol-4-karboxanilid;

penflufen

–

494793-67-8

Carc. 2

Xxxxxxx Acute 1

Aquatic Xxxxxxx 1

H351

H400

H410

GHS08

GHS09

Wng

H351

H410

M = 1

X = 1“

„616-232-00-6

xxxxxxxxxxxx (XXX);

xxxxxxxxx [(2X)-3-xxxxxx-1-{[1-(4-xxxxxxxxxxx)xxxxx]xxxxx}-1-xxxxxxxx-2-xx]xxxxxxxx

–

140923-17-7

Xxxx. 2

X351

XXX08

Xxx

X351“

„616-233-00-1

xxxxxxxxxx (XXX);

X-xxxxx-4,5-xxxxxxxx-2-(xxxxxxxxxxxxxx)xxxxxxx-3-xxxxxxxxxx

–

175217-20-6

XXXX XX 2

Xxxxxxx Xxxxxxx 2

X373

X411

XXX08

XXX09

Xxx

X373

X411“

„650-057-00-6

Xxxxxxx, xxxxxxx [xxxx xxxxxxxx xx xxxxxxx xx xxxxx xxxxxxxx Azadirachta xxxxxx xxx xxxxxxxx, xxxxxxxxxxx xxxxxxxxxxxxxx oxidem uhličitým]

283-644-7

84696-25-3

Aquatic Xxxxxxx 3

H412

H412“

2)

položky xxxxxxxxxxxx xxxxxxxxx xxxxxx 007-004-00-1; 014-018-00-1; 015-134-00-5; 015-181-00-1; 050-021-00-4; 050-027-00-7; 082-013-00-1; 603-014-00-0; 603-065-00-9; 605-019-00-3; 607-177-00-9; 607-256-00-8; 607-314-00-2; 609-041-00-4; 609-064-00-X; 613-112-00-5; 613-115-00-1; 613-125-00-6; 613-202-00-4; 613-259-00-5; 616–014–00–0 x 617–006–00-X se xxxxxxxxx xxxxxx položkami:

Indexové xxxxx

Xxxxxxxx xxxxx

Xxxxx ES

Číslo CAS

Klasifikace

Označení

Specifické xxxxxxx. xxxxxx, multiplikační xxxxxxx a XXX

Xxxxxxxx

Xxxx xxxx a xxxxxxxxx xxxxxxxxxxxxx

Xxxx standardních xxx x xxxxxxxxxxxxx

Xxxx xxxxxxxxxxx xxxxxxx a signálních xxxx

Xxxx xxxxxxxxxxxx xxx x xxxxxxxxxxxxx

Xxxx xxxxx. xxxxxxxxxxxx vět x xxxxxxxxxxxxx

„007-004-00-1

xxxxxxxx dusičná …% [X &xx; 70 %]

231-714-2

7697-37-2

Xx. Xxx. 2

Acute Xxx. 1

Skin Xxxx. 1 A

H272

H330

H314

GHS03

GHS06

GHS05

Dgr

H272

H330

H314

EUH071

Ox. Xxx. 2; X272: X ≥ 99 %

Xx. Xxx. 3; H272: 70 % ≤ X < 99 %

X“

„014-018-00-1

xxxxxxxxxxxxxxxxxxxxxxxxxxx;

[X4]

209-136-7

556-67-2

Xxxx. 2

Xxxxxxx Chronic 1

X361x ***

X410

XXX08

XXX09

Xxx

X361x ***

X410

X = 10“

„015-134-00-5

xxxxxxxxx-xxxxxx (XXX);

X-[2-(xxxxxxxxxxx)-6-xxxxxxxxxxxxxxx-4-xx]-X,X-xxxxxxxx-xxxxxxxxxxxxx

249-528-5

29232-93-7

Xxxxx Xxx. 4

XXXX XX 1

Xxxxxxx Acute 1

Xxxxxxx Xxxxxxx 1

X302

X372 (xxxxxxx xxxxxx)

X400

X410

XXX07

XXX08

XXX09

Xxx

X302

X372 (xxxxxxx systém)

H410

orální: XXX = 1&xxxx;414 xx/xx XX

X = 1&xxxx;000

X = 1&xxxx;000 “

„015-181-00-1

xxxxxx

232-260-8

7803-51-2

Xxxx. Xxx 1

Press. Xxx

Xxxxx Xxx. 1

Skin Xxxx. 1X

Xxxxxxx Xxxxx 1

X220

X330

X314

X400

XXX02

XXX04

XXX06

XXX05

XXX09

Xxx

X220

X330

X314

X400

xxxxxxxxx:

XXX = 10 xxxX (xxxxx)

X“

„050-021-00-4

xxxxxxxxxxxxxxxxxxxxx

222-583-2

3542-36-7

Xxxx. 1X

Xxxxx Xxx. 2

XXXX RE 1

Xxxxxxx Chronic 3

X360X

X330

X372 **

X412

XXX08

XXX06

Xxx

X360X

X330

X372 **

X412

Xxxx. 1X; X360 X: C ≥ 0,03 %

inhalační: XXX = 0.098 xx/X (xxxxx xxxx xxxx)“

„050-027-00-7

2-xxxxxxxxxx 10-ethyl-4,4-dioktyl-7-oxo-8-oxa-3,5-dithia-4-stannatetradekanoát; [XXXX]

239-622-4

15571-58-1

Xxxx. 1X

XXXX XX 1

Xxxxxxx Xxxxx 1

Aquatic Xxxxxxx 1

X360X

X372 (xxxxxxxx xxxxxx)

X400

X410

XXX08

XXX09

Xxx

X360X

X372 (xxxxxxxx systém)

H410“

„082-013-00-1

olověný prášek; [xxxxxx částic &xx; 1 xx]

231-100-4

7439-92-1

Xxxx. 1 X

Xxxx.

Xxxxxxx Acute 1

Xxxxxxx Xxxxxxx 1

X360XX

X362

X400

X410

XXX08

XXX09

Xxx

X360XX H362

H410

Repr. 1 A; H360D: X ≥ 0,03 %

X = 1

M = 10“

„603-014-00-0

2-xxxxxxxxxxx-1-xx;

xxxxxxxxxxxxxxxxxxxxxxxxxxxx

203-905-0

111-76-2

Xxxxx Xxx. 4*

Xxxxx Tox. 4

Xxxx Xxxxx. 2

Eye Irrit. 2

X332

X302

X315

X319

XXX07

Xxx

X332

X302

X315

X319

xxxxxx: ATE = 1&xxxx;200 xx/xx XX“

„603-065-00-9

x-xxx(2,3-xxxxxxxxxxxx)xxxxxx;

xxxxxxxxxxxxxxxxxxxxxxxxx

202-987-5

101-90-6

Xxxx. 1X

Xxxx. 2

Xxxxx Tox. 3

Xxxxx Xxx. 4

Xxxx Xxxxx. 2

Xxx Xxxxx. 2

Xxxx Sens. 1

Xxxxxxx Xxxxxxx 3

X350

X341

X311

X302

X315

X319

X317

X412

XXX08

XXX06

Xxx

X350

X341

X311

X302

X315

X319

X317

X412

xxxxxxxx: XXX = 300 xx/xx XX xxxxxx: XXX = 500 xx/xx XX“

„607-177-00-9

xxxxxxxxxx-xxxxxx (ISO);

methyl-2-[N-(4-methoxy-6-methyl-1,3,5-triazin-2-yl)-N-methylkarbamoylsulfamoyl]benzoát

401-190-1

101200-48-0

STOT RE 2

Xxxx Sens. 1

Xxxxxxx Xxxxx 1

Aquatic Chronic 1

X373

X317

X400

X410

XXX08

XXX07

XXX09

Xxx

X373

X317

X410

X = 100

X = 100“

„607-256-00-8

xxxxxxxxxxxx (XXX);

xxxxxx (X)-2-{2-[6-(2-xxxxxxxxxxx)xxxxxxxxx-4-xxxxx]xxxxx}-3-xxxxxxxxxxxxxx

–

131860-33-8

Xxxxx Xxx. 3

Xxxxxxx Xxxxx 1

Aquatic Xxxxxxx 1

X331

X400

X410

XXX06

XXX09

Xxx

X331

X410

xxxxxxxxx:

XXX = 0,7 xx/x (prach xxxx xxxx)

X = 10

X = 10“

„607-314-00-2

xxxxxxxxxxx (XXX);

(XX)-2-xxxxxx-2,3-xxxxxxx-3,3-xxxxxxxxxxxxxxxxxx-5-xx xxxxxxxxxxxxxx

247-525-3

26225-79-6

Xxxxxxx Acute 1

Xxxxxxx Xxxxxxx 1

X400

X410

XXX09

Xxx

X410

X = 1

X = 1“

„609-041-00-4

2,4-xxxxxxxxxxxx

200-087-7

51-28-5

Xxxxx Xxx. 3 *

Xxxxx Xxx. 3

Xxxxx Xxx. 2

XXXX XX 1

Xxxxxxx Xxxxx 1

X331

X311

X300

X372

X400

XXX06

XXX08

XXX09

Xxx

X331

X311

X300

X372

X400

xxxxxxxx: ATE = 300 xx/xx XX xxxxxx: XXX = 30 xx/xx XX“

„609-064-00-X

xxxxxxxxx (XXX);

2-[4-(xxxxxxxxxxxxxx)-2-xxxxxxxxxxxx]-1,3-xxxxxxxxxxxxxx

–

104206-82-8

Xxxx. 2

STOT XX 2

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

H361d

H373 (xxx, xxxxxxx xxxxxx)

X400

X410

XXX08

XXX09

Xxx

X361x

X373 (xxx, nervový xxxxxx)

X410

X = 10

X = 10“

„613-112-00-5

xxxxxxxxxx (XXX);

2-xxxxx-2X-xxxxxxxxxx-3-xx; [OIT]

247-761-7

26530-20-1

Acute Xxx. 2

Xxxxx Tox. 3

Xxxxx Xxx. 3

Xxxx Xxxx. 1

Eye Dam. 1

Xxxx Xxxx. 1 X

Xxxxxxx Acute 1 Xxxxxxx Xxxxxxx 1

X330

X311

X301

X314

X318

X317

X400

X410

XXX06

XXX05

XXX09

Xxx

X330

X311

X301

X314

X317

X410

XXX071

xxxxxxxxx: XXX = 0,27 xx/x (xxxxx nebo xxxx)

xxxxxxxx: ATE = 311 mg/kg XX xxxxxx: ATE = 125 xx/xx XX

Xxxx Xxxx. 1 A; X317: X ≥ 0,0015 %

X = 100

X = 100“

„613-115-00-1

xxxxxxxxx (XXX);

3-xxxxxxx-5-xxxxxxxxxxxxxx

233-000-6

10004-44-1

Xxxx. 2

Xxxxx Xxx. 4

Xxx Dam. 1

Xxxx Xxxx. 1

Xxxxxxx Xxxxxxx 2

X361x

X302

X318

X317

X411

XXX08

XXX07

XXX05

XXX09

Xxx

X361x

X302

X318

X317

X411

xxxxxx: ATE = 1&xxxx;600 xx/xx XX“

„613-125-00-6

xxxxxxxxxxx (XXX);

xxxxx-5-(4-xxxxxxxxxx)-X-xxxxxxxxxx-4-xxxxxx-2-xxx-3-xxxxxxxxxxx-xxxxxxxxxx

–

78587-05-0

Xxxxxxx Acute 1

Xxxxxxx Xxxxxxx 1

X400

X410

XXX09

Xxx

X410

X = 1

X = 1“

„613-202-00-4

pymetrozin (XXX);

(X)-4,5-xxxxxxx-6-xxxxxx-4-(3-xxxxxxxxxxxxxxxxxxxxx)-1,2,4-xxxxxxx-3(2X)-xx

–

123312-89-0

Xxxx. 2

Repr. 2

Xxxxxxx Xxxxxxx 1

X351

X361xx

X410

XXX08

XXX09

Xxx

X351

X361xx

X410

X = 1“

„613-259-00-5

xxxxxxxxxxx (XXX);

xxxxxxx směs: [2,4-xxxxx-(2-xxxxxx-1-xx)xxxxxxxxxxxx-3-xx]xxxxxx(1X)-xxx-xxxxxxxxxxxxx; [2,4-xxxxx-(2-xxxxxx-1-xx)xxxxxxxxxxxx-3-xx]xxxxxx(1X)-xxxxx-xxxxxxxxxxxxx

428-790-6

72963-72-5

Xxxx. 2

Acute Xxx. 4

Acute Xxx. 4

XXXX XX 2

Aquatic Xxxxx 1

Xxxxxxx Xxxxxxx 1

X351

X332

X302

X371 (nervový xxxxxx; xxxxxx, inhalační)

H400

H410

GHS08

GHS07

GHS09

Wng

H351

H332

H302

H371 (xxxxxxx xxxxxx; xxxxxx, xxxxxxxxx)

X410

xxxxxxxxx: XXX = 1,4 xx/x (xxxxx xxxx xxxx)

xxxxxx: XXX = 550 mg/kg XX

X = 10

M = 10“

„616-014-00-0

xxxxx-xx-xxxx; xxxxxxxxxxxxxxxxxx, ethyl(methyl)ketonoxim

202-496-6

96-29-7

Carc. 1X

Xxxxx Xxx. 4

Xxxxx Xxx. 3

XXXX XX 3

XXXX XX 1

STOT XX 2

Xxxx Irrit. 2

Xxx Xxx. 1

Skin Xxxx. 1

X350

X312

X301

X336

X370 (xxxxx xxxxxxx cesty)

H373 (xxxxxx xxxx)

X315

X318

X317

XXX08

XXX06

XXX05

Xxx

X350

X312

X301

X336

X370 (xxxxx dýchací xxxxx)

X373 (xxxxxx oběh)

H315

H318

H317

dermální: XXX = 1&xxxx;100 xx/xx TH xxxxxx: XXX = 100 xx/xx XX“

„617-006-00-X

xxx(α,α-xxxxxxxxxxxxxx)xxxxxxx

201-279-3

80-43-3

Xxx. Xxxxx. X

Xxxx. 1X

Xxxx Xxxxx. 2

Xxx Irrit. 2

Xxxxxxx Xxxxxxx 2

X242

X360X

X315

X319

X411

XXX02

XXX08

XXX07

XXX09

Xxx

X242

X360X

X315

X319

X411“

3)

xxxxxxx odpovídající xxxxxxxxx xxxxxx 601-064-00-8 x 607-693-00-4 xx xxxxxxx.